Jane Street Group LLC Sells 1,340,466 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Jane Street Group LLC decreased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 91.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 121,830 shares of the company’s stock after selling 1,340,466 shares during the quarter. Jane Street Group LLC’s holdings in Takeda Pharmaceutical were worth $1,732,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in TAK. Kovitz Investment Group Partners LLC increased its holdings in shares of Takeda Pharmaceutical by 7.0% during the third quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company’s stock worth $362,000 after buying an additional 1,670 shares in the last quarter. Stifel Financial Corp increased its holdings in Takeda Pharmaceutical by 103.9% during the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after purchasing an additional 224,594 shares in the last quarter. Quantinno Capital Management LP raised its position in Takeda Pharmaceutical by 2.9% in the 3rd quarter. Quantinno Capital Management LP now owns 361,713 shares of the company’s stock valued at $5,144,000 after purchasing an additional 10,258 shares during the last quarter. HighTower Advisors LLC boosted its stake in Takeda Pharmaceutical by 199.5% in the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock worth $1,744,000 after purchasing an additional 81,653 shares in the last quarter. Finally, Centiva Capital LP bought a new stake in shares of Takeda Pharmaceutical during the third quarter worth $265,000. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK opened at $13.17 on Thursday. The business has a fifty day moving average of $13.65 and a 200-day moving average of $13.88. The firm has a market cap of $41.91 billion, a PE ratio of 22.71, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.